Diagnostic Accuracy of Cerebral [F]FDG PET in Atypical Parkinsonism

Overview

Journal EJNMMI Res

Date 2023 Aug 12

PMID 37572162

Authors

Naba Jawad Houssein

Alexander Cuculiza Henriksen

Anne-Mette Hejl

Lisbeth Marner

Affiliations

Soon will be listed here.

Abstract

Background: Atypical parkinsonism (AP) often presents with Parkinson's symptoms but has a much worse long-term prognosis. The diagnosis is presently based on clinical criteria, but a cerebral positron emission tomography (PET) scan with [F]fluoro-2-deoxy-2-D-glucose ([F]FDG) may assist in the diagnosis of AP such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Lewy body dementia (DLB). Only few studies have evaluated the sensitivity and specificity of [F]FDG PET for separating the diseases in a mixed patient population, which we aim to assess in a retrospective material.

Results: We identified 156 patients referred for a cerebral [F]FDG PET for suspicion of AP during 2017-2019. The [F]FDG PET was analysed by a nuclear medicine specialist blinded to clinical information but with access to dopamine transporter imaging. The reference standard was the follow-up clinical diagnosis (follow-up: 6-72 months). The overall accuracy for correct classification was 74%. Classification sensitivity (95% confidence interval, CI) and specificity (95% CI) for MSA (n = 20) were 1.00 (0.83-1.00) and 0.91 (0.85-0.95), for DLB/Parkinson with dementia (PDD) (n = 26) were 0.81 (0.61-0.93) and 0.97 (0.92-0.99) and for CBD/PSP (n = 68) were 0.62 (0.49-0.73) and 0.97 (0.90-0.99).

Conclusions: Our results support the additional use of [F]FDG PET for the clinical diagnosis of AP with moderate to high sensitivity and specificity. Use of [F]FDG PET may be beneficial for prognosis and supportive treatment of the patients and useful for future clinical treatment trials.

Citing Articles

The value of PET/CT in the diagnosis and differential diagnosis of Parkinson's disease: a dual-tracer study.

Du X, Zhao H, Li Y, Dai Y, Gao L, Li Y NPJ Parkinsons Dis. 2024; 10(1):171.

PMID: 39256393 PMC: 11387816. DOI: 10.1038/s41531-024-00786-z.

Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson's disease: a systematic review and meta-analysis.

Wang J, Xue L, Jiang J, Liu F, Wu P, Lu J NPJ Digit Med. 2024; 7(1):17.

PMID: 38253738 PMC: 10803804. DOI: 10.1038/s41746-024-01012-z.

New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review.

Strobel J, Muller H, Ludolph A, Beer A, Sollmann N, Kassubek J Cells. 2023; 12(24).

PMID: 38132096 PMC: 10742083. DOI: 10.3390/cells12242776.

References

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J . Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018; 45(9):1534-1545. PMC: 6061481. DOI: 10.1007/s00259-018-4031-2. View

Mkhitarjan T, Areskeviciute A, Lund E, Marner L, Hejl A . Sporadic Fatal Insomnia Presenting with Initial Symptoms of Parkinsonism and Abnormal Dopamine Transporter Imaging. Mov Disord Clin Pract. 2022; 9(2):249-251. PMC: 8810444. DOI: 10.1002/mdc3.13385. View

Armstrong M, Litvan I, Lang A, Bak T, Bhatia K, Borroni B . Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80(5):496-503. PMC: 3590050. DOI: 10.1212/WNL.0b013e31827f0fd1. View

Murray R, Neumann M, Forman M, Farmer J, Massimo L, Rice A . Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology. 2007; 68(16):1274-83. DOI: 10.1212/01.wnl.0000259519.78480.c3. View

Baudrexel S, Seifried C, Penndorf B, Klein J, Middendorp M, Steinmetz H . The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Mov Disord. 2013; 29(3):380-7. DOI: 10.1002/mds.25749. View

Savica R, Grossardt B, Bower J, Boeve B, Ahlskog J, Rocca W . Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013; 70(11):1396-402. PMC: 4181848. DOI: 10.1001/jamaneurol.2013.3579. View

Stang C, Turcano P, Mielke M, Josephs K, Bower J, Ahlskog J . Incidence and Trends of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Population-Based Study. J Parkinsons Dis. 2019; 10(1):179-184. PMC: 7153436. DOI: 10.3233/JPD-191744. View

Feany M, Mattiace L, Dickson D . Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol. 1996; 55(1):53-67. DOI: 10.1097/00005072-199601000-00006. View

Blin J, Vidailhet M, Pillon B, Dubois B, FEVE J, Agid Y . Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord. 1992; 7(4):348-54. DOI: 10.1002/mds.870070409. View

10.

Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen N . EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020; 47(8):1885-1912. PMC: 7300075. DOI: 10.1007/s00259-020-04817-8. View

11.

Owen D, Yeo A, Gunn R, Song K, Wadsworth G, Lewis A . An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2011; 32(1):1-5. PMC: 3323305. DOI: 10.1038/jcbfm.2011.147. View

12.

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

13.

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

14.

Li L, Liu F, Li M, Lu J, Sun Y, Liang X . Clinical Utility of F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. Mov Disord. 2021; 36(10):2314-2323. DOI: 10.1002/mds.28672. View

15.

Hellwig S, Amtage F, Kreft A, Buchert R, Winz O, Vach W . [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012; 79(13):1314-22. DOI: 10.1212/WNL.0b013e31826c1b0a. View

16.

Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J . Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6. PMC: 2676993. DOI: 10.1212/01.wnl.0000324625.00404.15. View

17.

Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P . European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018; 25(10):1201-1217. DOI: 10.1111/ene.13728. View

18.

Teune L, Bartels A, de Jong B, Willemsen A, Eshuis S, de Vries J . Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010; 25(14):2395-404. DOI: 10.1002/mds.23291. View

19.

Tang C, Poston K, Eckert T, Feigin A, Frucht S, Gudesblatt M . Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010; 9(2):149-58. PMC: 4617666. DOI: 10.1016/S1474-4422(10)70002-8. View

20.

Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F . Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiol Dis. 2020; 139:104813. DOI: 10.1016/j.nbd.2020.104813. View